Academic Journal
Anti-Cancer Potential of a new Derivative of Caffeic Acid Phenethyl Ester targeting the Centrosome
| Τίτλος: | Anti-Cancer Potential of a new Derivative of Caffeic Acid Phenethyl Ester targeting the Centrosome |
|---|---|
| Συγγραφείς: | Catello Giordano, Jonatan Kendler, Maximilian Sexl, Sebastian Kollman, Maxim Varenicja, Boglárka Szabó, Gerald Timelthaler, Dominik Kirchhofer, Oldamur Hollóczki, Suzanne D. Turner, Richard Moriggl, Lukas Kenner, Mohamed Touaibia, Olaf Merkel |
| Πηγή: | issn:2213-2317 ; Redox Biology. |
| Στοιχεία εκδότη: | Elsevier |
| Έτος έκδοσης: | 2025 |
| Θεματικοί όροι: | Humans, Caffeic Acids Pharmacology, Caffeic Acids Chemistry, Phenylethyl Alcohol Analogs & Derivatives, Phenylethyl Alcohol Pharmacology, Phenylethyl Alcohol Chemistry, Centrosome Drug Effects, Centrosome Metabolism, Antineoplastic Agents Pharmacology, Antineoplastic Agents Chemistry, Apoptosis Drug Effects, Cell Line, Tumor, Cell Proliferation Drug Effects |
| Περιγραφή: | Anaplastic Large Cell Lymphoma (ALCL) is an aggressive T-cell lymphoma affecting children and young adults. About 30% of patients develop therapy resistance therefore new precision medicine drugs are highly warranted. Multiple rounds of structure-activity optimization of Caffeic Acid Phenethyl Ester have resulted in CM14. CM14 causes upregulation of genes involved in oxidative stress response and downregulation of DNA replication genes leading to G2/M arrest and subsequent apoptosis induction. In accordance with this, an unbiased proteomics approach, confocal microscopy and molecular modeling showed that TUBGCP2, member of the centrosomal ?-TuRC complex, is a direct interaction partner of CM14. CM14 overcomes ALK inhibitor resistance in ALCL and is also active in T-cell Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia. Interestingly, CM14 also induced cell death in docetaxel-resistant prostate cancer cells thus suggesting an unexpected role in solid cancers. Thus, we synthesized and thoroughly characterized a novel TUBGCP2 targeting drug that is active in ALCL but has also potential for other malignancies. |
| Τύπος εγγράφου: | article in journal/newspaper |
| Περιγραφή αρχείου: | application/pdf |
| Γλώσσα: | English |
| Relation: | isPartOf:https://phaidra.vetmeduni.ac.at/o:605[Open Access Publikationen]; https://phaidra.vetmeduni.ac.at/o:4027 |
| DOI: | 10.1016/j.redox.2025.103582 |
| Διαθεσιμότητα: | https://doi.org/10.1016/j.redox.2025.103582 https://phaidra.vetmeduni.ac.at/o:4027 |
| Rights: | http://creativecommons.org/licenses/by/4.0/ ; Copyright © 2025 The Authors ; open access |
| Αριθμός Καταχώρησης: | edsbas.8EEDA899 |
| Βάση Δεδομένων: | BASE |
καταχωρήστε σχόλιο πρώτοι!